Clinical trials: Metastatic Colorectal Cancer, completed
Colon Cancer Adenocarcinoma
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients
Protein arginine methylation is an important process, which regulates diverse cellular functions including cell proliferation, RNA stability, DNA repair and gene transcription.
- Trial name
- NCT02022995
- Where
- Taiwan
- Volunteers
- 180 people
- Sponsor
- National Taiwan University Hospital
Metastatic Colorectal Cancer, Colorectal Neoplasms
Resection Observatory
Primary Objective: -Evaluate the resection rate (R0/R1) in current practice for aflibercept in combination with irinotecan plus 5-fluorouracil (FOLFIRI) in patients treated for metastatic colorectal cancer (mCRC) after failure of…
- Trial name
- NCT05178745
- Testing
- Fluorouracil, Aflibercept, Irinotecan
- Volunteers
- 140 people
- Sponsor
- Sanofi
Colorectal Cancer
Phase II Trial of LBH589 in Refractory Colorectal Cancer
The purpose of this study is to determine the effects of the study drug, LBH589, on patients with metastatic colorectal cancer that has continued to grow despite previous treatment.
- Trial name
- NCT00690677
- Testing
- LBH589
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Swedish Medical Center
Metastatic Colorectal Cancer
Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer
The primary objective of this study is to assess the effect of treatment with ABX-EGF on best overall objective response rate by modified RECIST (confirmed complete or partial response) in Japanese subjects with metastatic…
- Trial name
- NCT00327119
- Testing
- ABX-EGF (panitumumab)
- Volunteers
- 50 people
- Sponsor
- Amgen
Renal Cell Cancer, Colorectal Cancer
Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST
The purpose of this study is to assess the influence of Sunitinib and Sorafenib on fatigue, quality of life and depression in patients with metastatic renal cell or colorectal cancer or GIST.
- Conditions
- Renal Cell Cancer, Colorectal Cancer, GIST
- Trial name
- NCT00979329
- Testing
- Questionnaires
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Radboud University Medical Center
Metastatic Colorectal Cancer
Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
This is a Phase 2, open-label, randomized, 3-arm trial investigating the efficacy of two Sym004 doses (Arm A and Arm B) compared with a control group (Arm C) in subjects with metastatic colorectal cancer (mCRC) and acquired…
- Trial name
- NCT02083653
- Testing
- Sym004 (12 mg/kg), Sym004 (9/6 mg/kg), Best Supportive Care (BSC)
- Where
- 54 sites in United States, Austria and 8 more
- Volunteers
- 254 people
- Sponsor
- Symphogen A/S
Metastatic Colorectal Cancer
"Cancersensor" Chemotherapy
Observational, non randomized study aimed at measuring the effect of chemotherapy in the urinary concentrations of physiological modified nucleosides in 30 patients with metastatic colorectal cancer.
- Trial name
- NCT01693861
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Metastatic Colorectal Cancer
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone
This clinical trial will be performed in previously untreated patients with metastatic colorectal cancer. The study will evaluate the safety, tolerability and efficacy of the study drug, CT-011, in combination with FOLFOX…
- Trial name
- NCT00890305
- Testing
- CT-011, FOLFOX
- Where
- 31 sites in United States, Bulgaria and 4 more
- Volunteers
- 171 people
- Sponsor
- Medivation, Inc.
Colorectal Cancer
Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00039273
- Testing
- panitumumab
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Colorectal Carcinoma
Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy
The purpose of this study is to determine safety and local tumor control of Embozene TANDEM Microspheres (40um TANDEM) loaded with Irinotecan to treat metastatic colorectal carcinoma (mCRC).
- Trial name
- MIRACLEIII (NCT02694562)
- Testing
- 40um Embozene TANDEM Microspheres
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Boston Scientific Corporation
Metastatic Colorectal Cancer
Biomarker - Panitumumab Response With KRAS Wild Type MCC
This is an exploratory study in which all eligible subjects are given Panitumumab according to the dose and schedule approved by Health Canada.
- Trial name
- NCT00853931
- Testing
- Panitumumab
- Where
- 3 sites in Canada
- Volunteers
- 52 people
- Sponsor
- British Columbia Cancer Agency
Metastatic Colorectal Cancer
Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation
A multicentre two-part phase I/II study evaluating response and safety of SORAFENIB in combination with irinotecan in the second line treatment or more of metastatic colorectal cancer with K-RAS mutation.
- Trial name
- NEXIRI (NCT00989469)
- Testing
- Nexavar (Sorafenib) and irinotecan (Campto)
- Where
- 5 sites in France
- Volunteers
- 64 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Metastatic Colorectal Cancer
Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.
AVETUX is a single arm multicentric phase II investigator initiated trial conducted by the Arbeitsgemeinschaft Internistische Onkologie (AIO) in 11 German sites in patients with previously untreated RAS/BRAF wildtype mCRC…
- Trial name
- AVETUX (NCT03174405)
- Testing
- Avelumab
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- AIO-Studien-gGmbH
Colonic Diseases, Cancer
Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen
1.1 To collect pathological tumor specimens of patients with metastatic colorectal cancer in a prospective fashion for correlative studies of response to an oxaliplatin based chemotherapy regimen.
- Trial name
- NCT00250029
- Testing
- Oxaliplatin
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- New Mexico Cancer Research Alliance
Colorectal Cancer
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- OMEGA (NCT00467142)
- Testing
- bevacizumab, fluorouracil, irinotecan hydrochloride
- Where
- France
- Volunteers
- 62 people
- Sponsor
- Institut Bergonié
Colorectal Cancer Metastatic
Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases
Chemotharapy plus targeted therapy regimen, as an adjuvant therapy, can effectively reduce the rate of both intrahepatic and extrahepatic recurrence in initially unresectable CRLM patients.
- Trial name
- NCT06027775
- Testing
- Targeted agent
- Volunteers
- 198 people
- Sponsor
- Fudan University
Colorectal Cancer, Neoplasm Metastasis
Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer
This trial is designed to investigate the safety, tolerability and the effectiveness when OSI-774 (tarceva) is combined with oxaliplatin and capecitabine in treating patients with metastatic colorectal cancer.
- Trial name
- NCT00123851
- Testing
- Tarceva (OSI-774), Capecitabine, Oxaliplatin
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Colorectal Cancer
Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer
A single-central,open-label,safety,pharmacokinetics,phase I study. Biological:Recombinant Anti-EGFr Antibody Two dose levels: Low-dose level patients received initial dose 100 mg/m2 and 4 weeks later 250 mg/m2 weekly maintenance…
- Trial name
- NCT03017807
- Testing
- Recombinant Anti-EGFr Antibody
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Metastatic Colon Cancer, Solid Tumor
Pembrolizumab + Poly-ICLC in MRP Colon Cancer
The main purpose of this study is to determine the dose of poly-ICLC that is safe and tolerable when it is combined with pembrolizumab in patients with colon cancer.
- Trial name
- NCT02834052
- Testing
- pembrolizumab, Poly-ICLC
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Asha Nayak
Colorectal Cancer
PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO)
Phase I/II clinical trial investigates the safety, tolerability, immunogenicity and preliminary efficacy of multiple doses of PolyPEPI1018 CRC vaccine as an add-on treatment to the standard-of-care maintenance therapy in patients…
- Trial name
- OBERTO (NCT03391232)
- Testing
- PolyPEPI1018 CRC Vaccine
- Where
- 2 sites in United States, Italy
- Volunteers
- 11 people
- Sponsor
- Treos Bio Zrt
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.